Integra LifeSciences Expects Q3 Revenue Of $372M-$382M Vs $432.11M Est, Adj EPS Of $0.36-$0.44 Vs $0.85 Est
Portfolio Pulse from Benzinga Newsdesk
Integra LifeSciences has revised its Q3 2024 revenue expectations to $372M-$382M, significantly below the $432.11M estimate. Adjusted EPS is expected to be $0.36-$0.44, also below the $0.85 estimate. For the full year 2024, the company expects revenue of $1.609-$1.629 billion and adjusted EPS of $2.41-$2.57.
July 29, 2024 | 10:03 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Integra LifeSciences has significantly lowered its Q3 2024 revenue and adjusted EPS expectations, which are well below analyst estimates. This revision is likely due to quality and labeling compliance issues and significant investments in quality and compliance improvement.
The significant downward revision in both revenue and adjusted EPS for Q3 2024, well below analyst estimates, is likely to negatively impact the stock price in the short term. The revisions are attributed to quality and labeling compliance issues and substantial investments in quality and compliance improvement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100